查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球视网膜疾病治疗市场 2023-2030
市场调查报告书
商品编码
1380424

全球视网膜疾病治疗市场 2023-2030

Global Retinal Disorder Treatment Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 198 Pages | 商品交期: 2-3个工作天内

价格

预计在预测期（2023-2030年），全球视网膜疾病治疗市场将以11.2%的CAGR成长。在与失明的持久战中，治疗主要视网膜疾病及其相关发病率在过去二十年中一直在稳步增长。黄斑部病变治疗视网膜疾病的日益普及是支持全球市场成长的关键因素。因此，市场参与者也专注于推出基于黄斑部病变的视网膜疾病治疗解决方案，以进一步促进市场成长。例如，2023年2月，生物製药公司Apellis Pharmaceuticals, Inc.宣布美国（FDA）批准SYFOVRE（TM）（pegcetacoplan注射液）用于治疗老年黄斑继发的地图样萎缩（GA）变性（AMD） 。 SYFOVRE 是第一个也是唯一一个获得 FDA 批准的 GA 治疗方法，GA 是导致失明的主要原因，影响着美国超过 100 万人和全球 500 万人。

根据国际防盲机构（IAPB）统计，2020年，中国和印度的失明和视力障碍负担合计占全球的49.0%，而两国人口占全球人口的37.0%。

目录

第 1 章：报告摘要

  • 目前行业分析及成长潜力展望
  • 研究方法和工具
  • 市场区隔
    • 按细分
    • 按地区

第 2 章：市场概述与见解

  • 报告范围
  • 分析师见解和当前市场趋势
    • 主要发现
    • 建议
    • 结论

第 3 章：竞争格局

  • 主要公司分析
  • Allergan, Inc.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Novartis AG
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Regeneron Pharmaceuticals, Inc.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • 关键策略分析

第 4 章：市场细分

  • 按适应症分類的全球视网膜疾病治疗市场
    • 糖尿病性视网膜病变
    • 黄斑部病变
    • 视网膜剥离
    • 视网膜母细胞瘤
    • 其他（糖尿病眼疾、黄斑皱襞、黄斑裂孔、飞蚊症）
  • 按剂型分類的全球视网膜疾病治疗市场
    • 凝胶
    • 眼睛解决方案
    • 胶囊和片剂
    • 眼药水
    • 药膏
  • 按配销通路的全球视网膜疾病治疗市场
    • 医院药房
    • 零售药局
    • 网上销售

第 5 章：区域分析

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 义大利
    • 西班牙
    • 法国
    • 欧洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 世界其他地区

第 6 章：公司简介

  • Adverum Biotechnologies
  • Aldeyra Therapeutics, Inc.
  • Alimera Sciences Inc.
  • Bausch Health Companies Inc.
  • Biogen Inc.
  • Clearside Biomedical, Inc.
  • F. Hoffmann-La Roche AG
  • Genentech, Inc.
  • Graybug Vision, Inc.
  • Gyroscope Therapeutics Holdings PLC
  • Iveric Bio, Inc.
  • Kala Pharmaceuticals
  • Kodiak Sciences
  • Otsuka Pharmaceutical Co Ltd.
  • Santen Pharmaceutical Co., Ltd.
  • Sentis Pharma Pvt Ltd.
  • Spark Therapeutics
Product Code: OMR2027833

Title: Global Retinal Disorder Treatment Market Size, Share & Trends Analysis Report by Indication (Diabetic Retinopathy, Macular Degeneration, Retinal Detachment, Retinoblastoma and Other), by Dosage Form (Gels, Eye Solutions, Capsules & Tablets, Eye Drops and Ointments), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Sales),Forecast Period (2023-2030).

The global retinal disorder treatment market is anticipated to grow at a CAGR of 11.2% during the Forecast Period (2023-2030). Treating the main retinal diseases in the everlasting war against blindness and its associated morbidity has been growing steadily over the last two decades. The growing adoption of macular degeneration treatment for retinal disorder key factor supporting the growth of the market globally. Hence, the market players are also focusing on introducing macular degeneration-based retinal disorder treatment solutions that further bolster the market growth. For instance, in February 2023, Apellis Pharmaceuticals, Inc., a biopharmaceutical company in complement, announced that the US (FDA) approved SYFOVRE™ (pegcetacoplan injection) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). SYFOVRE is the first and only FDA-approved treatment for GA, a leading cause of blindness that impacts more than one million people in the US and five million people globally.

According to the International Agency for the Prevention of Blindness (IAPB), in 2020, China and India together accounted for 49.0% of the global total burden of blindness and vision impairment, while their populations represent 37.0% of the global population.

Segmental Outlook

The global retinal disorder treatment market is segmented on the indication, dosage form, and distribution channel. Based on the indication, the market is sub-segmented into diabetic retinopathy, macular degeneration, retinal detachment, retinoblastoma and others (diabetic eye disease, macular pucker, macular hole, floaters). Based on the dosage form, the market is sub-segmented into gels, eye solutions, capsules & tablets, eye drops and ointments. Further, on the basis of distribution channel, the market is sub-segmented into hospital pharmacies, retail pharmacies and online sales. Among the dosage form, the eye solutions sub-segment is anticipated to hold a considerable share of the market owing to the rise in

The Macular Degeneration Sub-Segment is Anticipated to Hold a Considerable Share of the Global Retinal Disorder Treatment Market

Among the Indications, the macular degeneration sub-segment is expected to hold a considerable share of the global retinal disorder treatment market. The segmental growth is attributed to the growing treatments of macular degeneration including nutritional supplements, medications, photodynamic therapy (PDT) and laser therapy. US marks an important moment for patients, healthcare providers, payers, and the entire healthcare system. Patients suffering from retinal vascular disorders now have a more affordable treatment option. For instance, in June 2022, Biogen Inc. and Samsung Bioepis Co., Ltd. announced that BYOOVIZ™ (ranibizumab-nuna), a biosimilar referencing LUCENTIS® (ranibizumab)i launched in the US. Healthcare provider engagement, promotional activity, and collaborations with professional societies and patient advocacy groups have commenced and BYOOVIZ is commercially available through major distributors across the US.

Regional Outlook

The global retinal disorder treatment market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America. Among these, North America is anticipated to hold a prominent share of the market across the globe, owing to the growing geriatric population, the increasing launch of novel products, and enhanced awareness levels about eye conditions. The key market players include AbbVie Inc., Genentech, Inc., Graybug Vision, Inc., Ocular Therapeutix, Regeneron Pharmaceuticals, Inc. others.

The Asia-Pacific Region is Expected to Grow at a Significant CAGR in the Global Retinal Disorder Treatment Market

Among all regions, the Asia-Pacific regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to high healthcare expenditure and good-quality medical facilities. The increasing awareness among the population about early diagnosis & treatment, rising disposable income, and availability of effective and efficient treatment methods. For instance, as of 2021, India has 74 million diabetics, while 12.5 million of these suffer from diabetic retinopathy of some form. Thus, the presence of a high number of target patients is creating opportunities in the region.

Age-related macular degeneration treatment is expected to exhibit lucrative growth, as multiple market players are increasingly focusing on R&D to develop innovative treatments. The key market players include Kubota Pharmaceutical Holdings Co., Ltd., Otsuka Pharmaceutical Co. Ltd., Santen Pharmaceutical Co. Ltd., Senju Pharmaceutical Co., Ltd., Sentis Pharma Pvt Ltd., Sun Pharmaceutical Industries Ltd. and others.

Market Players Outlook

The major companies serving the retinal disorder treatment market include: Allergan, Inc., Bausch Health Companies Inc., Genentech, Inc., Novartis AG, Regeneron Pharmaceuticals, Inc. and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in September 2021, AbbVie collaborated with RegenxBio to develop and market a potential one-time gene therapy, RGX-314, for treating wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global retinal disorder treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Allergan, Inc.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Novartis AG
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Regeneron Pharmaceuticals, Inc.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Retinal Disorder Treatment Market by Indication
    • 4.1.1. Diabetic Retinopathy
    • 4.1.2. Macular Degeneration
    • 4.1.3. Retinal Detachment
    • 4.1.4. Retinoblastoma
    • 4.1.5. Other (Diabetic Eye Disease, Macular Pucker, Macular Hole, Floaters)
  • 4.2. Global Retinal Disorder Treatment Market by Dosage Form
    • 4.2.1. Gels
    • 4.2.2. Eye Solutions
    • 4.2.3. Capsules & Tablets
    • 4.2.4. Eye Drops
    • 4.2.5. Ointments
  • 4.3. Global Retinal Disorder Treatment Market by Distribution Channel
    • 4.3.1. Hospital Pharmacies
    • 4.3.2. Retail Pharmacies
    • 4.3.3. Online Sales

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Adverum Biotechnologies
  • 6.2. Aldeyra Therapeutics, Inc.
  • 6.3. Alimera Sciences Inc.
  • 6.4. Bausch Health Companies Inc.
  • 6.5. Biogen Inc.
  • 6.6. Clearside Biomedical, Inc.
  • 6.7. F. Hoffmann-La Roche AG
  • 6.8. Genentech, Inc.
  • 6.9. Graybug Vision, Inc.
  • 6.10. Gyroscope Therapeutics Holdings PLC
  • 6.11. Iveric Bio, Inc.
  • 6.12. Kala Pharmaceuticals
  • 6.13. Kodiak Sciences
  • 6.14. Otsuka Pharmaceutical Co Ltd.
  • 6.15. Santen Pharmaceutical Co., Ltd.
  • 6.16. Sentis Pharma Pvt Ltd.
  • 6.17. Spark Therapeutics

LIST OF TABLES

  • 1. GLOBAL RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY INDICATION, 2022-2030 ($ MILLION)
  • 2. GLOBAL DIABETIC RETINOPATHY DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL RETINAL MACULAR DEGENERATION DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL RETINAL DETACHMENT DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL RETINAL RETINOBLASTOMA DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL OTHERS RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 7. GLOBAL RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DOSAGE FORM, 2022-2030 ($ MILLION)
  • 8. GLOBAL GELS FOR RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL EYE SOLUTIONS FOR RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 10. GLOBAL CAPSULES & TABLETS FOR RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 11. GLOBAL EYE DROPS FOR RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 12. GLOBAL OINTMENTS FOR RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 13. GLOBAL RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNELS, 2022-2030 ($ MILLION)
  • 14. GLOBAL RETINAL DISORDER TREATMENT IN HOSPITAL PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15. GLOBAL RETINAL DISORDER TREATMENT IN RETAIL PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 16. GLOBAL RETINAL DISORDER TREATMENT IN ONLINE SALES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 17. GLOBAL RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 18. NORTH AMERICAN RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 19. NORTH AMERICAN RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY INDICATION, 2022-2030 ($ MILLION)
  • 20. NORTH AMERICAN RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DOSAGE FORM, 2022-2030 ($ MILLION)
  • 21. NORTH AMERICAN RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 22. EUROPEAN RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 23. EUROPEAN RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY INDICATION, 2022-2030 ($ MILLION)
  • 24. EUROPEAN RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DOSAGE FORM, 2022-2030 ($ MILLION)
  • 25. EUROPEAN RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 26. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 27. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY INDICATION, 2022-2030 ($ MILLION)
  • 28. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DOSAGE FORM, 2022-2030 ($ MILLION)
  • 29. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 30. REST OF THE WORLD RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY INDICATION, 2022-2030 ($ MILLION)
  • 31. REST OF THE WORLD RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DOSAGE FORM, 2022-2030 ($ MILLION)
  • 32. REST OF THE WORLD RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL RETINAL DISORDER TREATMENT MARKET SHARE BY INDICATION, 2022 VS 2030 (%)
  • 2. GLOBAL DIABETIC RETINOPATHY DISORDER TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL RETINAL MACULAR DEGENERATION DISORDER TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL RETINAL DETACHMENT DISORDER TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL RETINOBLASTOMA DISORDER TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL OTHERS RETINAL DISORDER TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL RETINAL DISORDER TREATMENT MARKET SHARE BY DOSAGE FORM, 2022 VS 2030 (%)
  • 8. GLOBAL GELS FOR RETINAL DISORDER TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL EYE SOLUTIONS FOR RETINAL DISORDER TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL CAPSULES & TABLETS FOR RETINAL DISORDER TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 11. GLOBAL EYE DROPS FOR RETINAL DISORDER TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL OINTMENTS FOR RETINAL DISORDER TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL RETINAL DISORDER TREATMENT MARKET SHARE BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
  • 14. GLOBAL RETINAL DISORDER TREATMENT IN HOSPITAL PHARMACIES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 15. GLOBAL RETINAL DISORDER TREATMENT IN RETAIL PHARMACIES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 16. GLOBAL RETINAL DISORDER TREATMENT IN ONLINE SALES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 17. GLOBAL RETINAL DISORDER TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 18. US RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. UK RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. FRANCE RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. ITALY RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. SPAIN RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. REST OF EUROPE RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. INDIA RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. CHINA RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. JAPAN RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. SOUTH KOREA RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 30. REST OF ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 31. REST OF THE WORLD RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)